Bone Sarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BNS007 MIFTS: 44	Bone Sarcoma Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Bone Sarcoma

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

bone sarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁹

Rare bone diseases

External Ids:

UMLS via Orphanet ⁷³ C0029463 C1704327

Orphanet ⁵⁹ ORPHA223727

Sources

Summaries for Bone Sarcoma

MalaCards based summary : Bone Sarcoma is related to exanthem and mesenchymoma. An important gene associated with Bone Sarcoma is MTAP (Methylthioadenosine Phosphorylase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Dasatinib have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are cardiovascular system and hematopoietic system

Sources

Related Diseases for Bone Sarcoma

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)

#	Related Disease	Score	Top Affiliating Genes
1	exanthem	30.2	IL6 IL1RN CTLA4
2	mesenchymoma	30.1	MB DES
3	hematopoietic stem cell transplantation	30.0	IL6 IL10 CTLA4
4	paracoccidioidomycosis	30.0	IL6 IL10 CTLA4
5	osteomyelitis	29.9	IL6 IL1RN IL10 CXCL8
6	bilateral retinoblastoma	29.9	MB DES
7	toxic shock syndrome	29.9	IL6 IL10 CXCL8
8	synovitis	29.7	IL6 IL1RN CXCL8
9	bone inflammation disease	29.4	IL6 IL1RN IL10 CXCL8
10	ewing sarcoma	29.1	IL6 DES CTLA4 CSF3 CCNB3 BCOR
11	kaposi sarcoma	28.9	SRC IL6 CXCL8
12	osteogenic sarcoma	11.7
13	diaphyseal medullary stenosis with malignant fibrous histiocytoma	11.3
14	li-fraumeni syndrome	11.1
15	li-fraumeni syndrome 2	11.1
16	sarcoma	10.8
17	spindle cell sarcoma	10.8
18	leukoregulin	10.6	CXCL8 CSF1
19	soft tissue sarcoma	10.6
20	chondrosarcoma	10.6
21	tungiasis	10.6	IL10 CXCL8
22	neurosyphilis	10.5	IL10 CXCL8
23	scabies	10.5	IL10 CXCL8
24	recurrent corneal erosion	10.5	IL6 CXCL8
25	vulvovaginitis	10.5	IL10 CXCL8
26	bagassosis	10.5	IL6 CXCL8
27	necatoriasis	10.5	IL10 CXCL8
28	giant cell myocarditis	10.5	MB DES
29	streptococcal toxic-shock syndrome	10.5	IL6 CXCL8
30	kidney sarcoma	10.5	MB BCOR
31	malignant triton tumor	10.4	MB DES
32	eye lymphoma	10.4	IL6 IL10
33	botryoid rhabdomyosarcoma	10.4	MB DES
34	vulvar vestibulitis syndrome	10.4	IL1RN IL1R1
35	engraftment syndrome	10.4	CXCL8 CSF3
36	anca-associated vasculitis	10.4	IL6 CTLA4
37	myofibroma	10.3	MB DES
38	pouchitis	10.3	IL1RN IL10 CXCL8
39	fasciitis	10.3	IL6 DES CXCL8
40	spindle cell rhabdomyosarcoma	10.3	MB DES
41	juvenile ankylosing spondylitis	10.3	IL6 IL1RN
42	meningitis	10.3	IL6 IL10 CXCL8
43	monocytic leukemia	10.3	IL6 CXCL8 CSF1
44	peptic ulcer disease	10.3	IL1RN IL10 CXCL8
45	periodontitis	10.3	IL6 IL10 CXCL8
46	acute transverse myelitis	10.3	IL6 IL10 CXCL8
47	uveitis	10.3	IL1R1 IL10 CTLA4
48	transverse myelitis	10.3	IL6 IL10 CXCL8
49	funisitis	10.3	IL6 IL10 CXCL8
50	leiomyosarcoma	10.3

Graphical network of the top 20 diseases related to Bone Sarcoma:

Sources

Symptoms & Phenotypes for Bone Sarcoma

MGI Mouse Phenotypes related to Bone Sarcoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.22	BCOR CSF1 CTLA4 DES IL10 IL1R1
2	hematopoietic system	MP:0005397	10.21	BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
3	immune system	MP:0005387	10.18	BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
4	cellular	MP:0005384	10.16	BCOR CSF1 DES IL10 IL1R1 IL1RN
5	mortality/aging	MP:0010768	10.03	BCOR CSF1 CTLA4 DES IL10 IL1R1
6	integument	MP:0010771	10.02	CSF1 CSF3 CTLA4 IL10 IL1R1 IL1RN
7	liver/biliary system	MP:0005370	9.87	CSF1 CTLA4 IL10 IL1R1 IL6 MTAP
8	muscle	MP:0005369	9.7	CSF1 DES IL10 IL1R1 IL6 MB
9	respiratory system	MP:0005388	9.61	CSF1 CTLA4 IL10 IL1R1 IL6 MB
10	skeleton	MP:0005390	9.23	CSF1 CTLA4 IL10 IL1R1 IL1RN IL6

Sources

Drugs & Therapeutics for Bone Sarcoma

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Dacarbazine

Approved, Investigational

Phase 2

4342-03-4

5351166

Vincristine

Approved, Investigational

Phase 2

57-22-7, 2068-78-2

5978

nivolumab

Approved

Phase 1, Phase 2

946414-94-4

Sunitinib

Approved, Investigational

Phase 1, Phase 2

557795-19-4, 341031-54-7

5329102

Fludarabine

Approved

Phase 2

21679-14-1, 75607-67-9

30751

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Vidarabine

Approved, Investigational

Phase 2

24356-66-9

21704 32326

Pembrolizumab

Approved

Phase 2

1374853-91-4

Cisplatin

Approved

Phase 1, Phase 2

15663-27-1

84093 441203 2767

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

126941

leucovorin

Approved

Phase 2

58-05-9

143 6006

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Levoleucovorin

Approved, Investigational

Phase 2

68538-85-2

Irinotecan

Approved, Investigational

Phase 2

100286-90-6, 97682-44-5

60838

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Serine

Approved, Nutraceutical

Phase 2

56-45-1

5951

Vitamin C

Approved, Nutraceutical

Phase 2

50-81-7

54670067 5785

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Exatecan

Investigational

Phase 2

171335-80-1

Camptothecin

Experimental

Phase 2

7689-03-4

Emodepside

Investigational, Vet_approved

Phase 2

155030-63-0

Antihypertensive Agents

Phase 2

Veratrum Alkaloids

Phase 2

Antifungal Agents

Phase 2

Antibodies, Monoclonal

Phase 2

Imatinib Mesylate

Phase 2

220127-57-1

123596

Antineoplastic Agents, Phytogenic

Phase 2

Tubulin Modulators

Phase 2

Cyclosporins

Phase 2

Calcineurin Inhibitors

Phase 2

Anti-Infective Agents

Phase 2

Pharmaceutical Solutions

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 1, Phase 2

Angiogenesis Modulating Agents

Phase 1, Phase 2

Analgesics

Phase 2

Analgesics, Non-Narcotic

Phase 2

Peripheral Nervous System Agents

Phase 2

Vidarabine Phosphate

Phase 2

Anti-HIV Agents

Phase 2

Anti-Retroviral Agents

Phase 2

Interleukin-2

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins

Phase 2

Interventional clinical trials:

(show all 39)

#	Name	Status	NCT ID	Phase	Drugs
1	PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional	Unknown status	NCT00807261	Phase 2	Gemcitabine and Docetaxel
2	A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma	Completed	NCT01310816	Phase 2	IPI-926;Placebo Arm
3	A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas	Completed	NCT01016015	Phase 2	Temsirolimus
4	Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society	Completed	NCT00031915	Phase 2	imatinib mesylate
5	A Phase II Trial of Dasatinib in Advanced Sarcomas	Completed	NCT00464620	Phase 2	Dasatinib
6	Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group	Completed	NCT00041236	Phase 2	exatecan mesylate
7	Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma	Completed	NCT02546544	Phase 2	Linsitinib
8	Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy	Completed	NCT00001880	Phase 2	methotrexate;cyclosporin
9	Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma	Completed	NCT00802880	Phase 2	Dacarbazine
10	A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide	Completed	NCT00267046	Phase 2	Palifermin;Placebo;Adriamycin (Doxorubicin);Ifosfamide;Vincristine;Cisplatin
11	Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas	Recruiting	NCT03277924	Phase 1, Phase 2	Sunitinib 37.5 MG [Sutent];Nivolumab 10 MG/ML [Opdivo]
12	Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	Recruiting	NCT03449108	Phase 2	Cyclophosphamide;Fludarabine;Fludarabine Phosphate
13	SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas	Active, not recruiting	NCT02301039	Phase 2	Pembrolizumab
14	Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases	Not yet recruiting	NCT03965234	Phase 1, Phase 2	Cisplatin
15	Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration	Not yet recruiting	NCT04040205	Phase 2	Abemaciclib
16	A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults	Suspended	NCT03468075	Phase 2	Ascorbate;Gemcitabine
17	A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma	Terminated	NCT00880542	Phase 2	sorafenib;Ifosfamide
18	A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma	Terminated	NCT02022358	Phase 2	Glucarpidase;Methotrexate;Folinic Acid
19	Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas	Terminated	NCT00544778	Phase 2	dexrazoxane hydrochloride;doxorubicin hydrochloride;ifosfamide;irinotecan hydrochloride
20	An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma	Completed	NCT01896505	Phase 1	KCP-330
21	In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas	Recruiting	NCT02811523	Phase 1	Doxorubicin
22	To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma	Recruiting	NCT03462316	Phase 1
23	A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy	Terminated	NCT01491594	Phase 1	Eltrombopag
24	A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors	Terminated	NCT01204450	Phase 1	Temsirolimus;Valproic Acid
25	Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults	Unknown status	NCT01780779
26	Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity	Unknown status	NCT01533779
27	Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients	Unknown status	NCT02845583
28	Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment	Completed	NCT00824083
29	A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years	Completed	NCT02986503		Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
30	Long Term Clinical and Functional Outcome in Patients Operated on Van Ness-Borggreve Rotationplasty for Lower Limnb Bone Tumor	Completed	NCT03385694
31	Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors	Completed	NCT00598741
32	Clinical Evaluation for Sarcoma Originated From Bone	Recruiting	NCT03358992
33	Pre-Surgical Supervised Exercise for Bone Cancer Patients	Recruiting	NCT02893397
34	Transcultural Validation of MSTS and TESS Questionnaire	Recruiting	NCT03765970
35	Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas	Recruiting	NCT03442465
36	Etiosarc: Study of the Environmental Aetiology (Environment, Occupations and Lifestyle) of Sarcomas (Soft Tissue, Visceral and Bone) From a Multicenter French Population-based Case-control Study Among Adults.	Recruiting	NCT03670927
37	DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study	Active, not recruiting	NCT00525057		Dalteparin
38	Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone	Enrolling by invitation	NCT03134742
39	A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	Not yet recruiting	NCT04055220		Treatment by Regorafenib;Treatment by Placebo

Search NIH Clinical Center for Bone Sarcoma

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :

Doxorubicin

Sources

Genetic Tests for Bone Sarcoma

Sources

Anatomical Context for Bone Sarcoma

MalaCards organs/tissues related to Bone Sarcoma:

⁴¹

Bone, Lung, T Cells, Breast, Brain, Neutrophil, Bone Marrow

Sources

Publications for Bone Sarcoma

Articles related to Bone Sarcoma:

(show top 50) (show all 770)

#	Title	Authors	PMID	Year
1	The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. ³⁸	Miao W...Song D	31253399	2019
2	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. ³⁸	Nanni P...Scotlandi K	31434953	2019
3	Bone Sarcoma With EWSR1-NFATC2 Fusion: Sarcoma With Varied Morphology and Amplification of Fusion Gene Distinct From Ewing Sarcoma. ³⁸	Yau DTW...Chan ACL	30714449	2019
4	Ion channels in sarcoma: pathophysiology and treatment options. ³⁸	Aung T...Haerteis S	31377822	2019
5	[The importance of radiology in bone sarcoma diagnostics : Initial and advanced diagnostics]. ³⁸	Vieth V	31392388	2019
6	Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. ³⁸	Sambri A...Manfrini M	31093984	2019
7	SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. ³⁸	Heng-Maillard MA...Andre N	30920117	2019
8	Oncological and endoprosthetic outcomes of bone sarcoma patients: a nationwide cohort study. ³⁸	Mavcic B...Martincic D	31324968	2019
9	CORR Insights®: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. ³⁸	Lozano-Calderon SA	31135541	2019
10	CORR® Tumor Board: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. ³⁸	Anderson ME...Vargas SO	31169622	2019
11	Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. ³⁸	Bosma SE...Dijkstra PDS	31107331	2019
12	Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). ³⁸	Gomez-Brouchet A...GROUPOS (GSF-GETO RESOS)	30962172	2019
13	Deep integrative analysis of microRNA-mRNA regulatory networks for biomarker and target discovery in chondrosarcoma. ³⁸	Sui J...Kong Y	30520120	2019
14	Bone sarcoma incidence in the Netherlands. ³⁸	Goedhart LM...Jutte PC	30903831	2019
15	Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas. ³⁸	Lhuissier E...Bauge C	31241814	2019
16	Resection margins obtained with patient-specific instruments for resecting primary pelvic bone sarcomas: A case-control study. ³⁸	Evrard R...Docquier PL	30982774	2019
17	Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. ³⁸	White VM...Anazodo A	30822262	2019
18	Identifying bone sarcoma survivors facing psychosocial challenges. A study of trajectories following treatment. ³⁸	Fauske L...Bjorndal A	31184795	2019
19	Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. ³⁸	Stamatopoulos A...Tsiridis E	30956944	2019
20	Current review of surgical management options for extremity bone sarcomas. ³⁸	Cirstoiu C...Nica M	31191985	2019
21	Effective nutritional status screening in orthopaedic oncology patients and post-operative complications. ³⁸	Eu CW...Yasin NF	31084248	2019
22	Decision-making in Orthopaedic Oncology: Does Cognitive Bias Affect a Virtual Patient's Choice Between Limb Salvage and Amputation? ³⁸	Gurich RW...Thompson MJ	31173578	2019
23	Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. ³⁸	Rainusso N...Yustein JT	30548185	2019
24	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. ³⁸	Haas RLM...Gronchi A	30602058	2019
25	Serum Biomarkers as Prognostic Factors for Metastatic Sarcoma. ³⁸	Aggerholm-Pedersen N...Safwat A	30744933	2019
26	Advances in immune checkpoint inhibitors for bone sarcoma therapy. ³⁸	Thanindratarn P...Duan Z	30775238	2019
27	H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. ³⁸	Makise N...Yoshida A	30291346	2019
28	Chordoma: update on disease, epidemiology, biology and medical therapies. ³⁸	Frezza AM...Stacchiotti S	30585858	2019
29	The impact of severe late-effects after 12 Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010). ³⁸	Freycon F...Trombert-Paviot B	30978121	2019
30	Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/β-catenin signaling. ³⁸	Chen C...Ma X	30140042	2019
31	Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California. ³⁸	Seto T...Pan M	30889920	2019
32	Pediatric Soft Tissue and Bone Sarcomas in Tanzania: Epidemiology and Clinical Features. ³⁸	Siwillis EM...Million L	30917068	2019
33	Adjuvant Biophysical Therapies in Osteosarcoma. ³⁸	Carina V...Giavaresi G	30871044	2019
34	Short Term Complications and Functional Results of Sarcoma Limb Salvage Surgeries. ³⁸	Gharehdaghi M...Hosseini R	31211194	2019
35	Does Patellar Tendon Repair With Gastrocnemius Flap Augmentation Effectively Restore Active Extension After Proximal Tibial Sarcoma Resection? ³⁸	Cipriano CA...McDonald DJ	30461516	2019
36	Use of Vascularized Fibular Free Flap in the Reconstruction of the Femur in Pediatric and Adolescent Bone Sarcomas: Complications and Functional Outcome. ³⁸	Ghoneimy AME...Kamal N	30121051	2019
37	New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ³⁸	Tanaka K...Ozaki T	30423153	2019
38	Health professional perceptions of communicating with adolescents and young adults about bone cancer clinical trial participation. ³⁸	Lavender V...Pearce S	29978324	2019
39	Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study. ³⁸	Berner K...Bruland OS	30568874	2019
40	Synovial sarcoma of bone: Sarcoma typically of soft tissues presenting as a primary bone tumor. ³⁸	Caracciolo JT...Binitie O	30425775	2019
41	Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. ³⁸	Ali NM...Latif F	30281149	2019
42	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. ³⁸	van Maldegem A...Gelderblom H	30082492	2019
43	Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-κB pathway. ³⁸	Avnet S...Baldini N	31285947	2019
44	New Advances in the Study of Bone Tumors: A Lesson From the 3D Environment. ³⁸	Cortini M...Avnet S	31316395	2019
45	HACE1 is a potential tumor suppressor in osteosarcoma. ³⁸	El-Naggar AM...Sorensen PH	30622235	2019
46	The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. ³⁸	Schiavone K...Heymann D	31134502	2019
47	Growing Without Pain: The Noninvasive Expandable Prosthesis is Boon for Children with Bone Cancer, as well as Their Surgeons! ³⁸	Gundavda MK...Agarwal MG	30905999	2019
48	Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. ³⁸	Weidema M...Desar I	30264644	2019
49	The clinical outcomes of total femur prosthesis in patients with musculoskeletal tumors. ³⁸	Kakimoto T...Sudo A	31250806	2019
50	Murine Models of Bone Sarcomas. ³⁸	Jacques C...Heymann D	30729474	2019

Sources

Genes for Bone Sarcoma

Genes related to Bone Sarcoma (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MTAP	Methylthioadenosine Phosphorylase	Protein Coding	17.53	GeneCards inferred via : Disorders (show sections)
2	CSF1	Colony Stimulating Factor 1	Protein Coding	16.68	GeneCards inferred via : Publications (show sections)
3	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	16.68	GeneCards inferred via : Publications (show sections)
4	BCOR	BCL6 Corepressor	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
5	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
6	DES	Desmin	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
7	GSTA1	Glutathione S-Transferase Alpha 1	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
8	IL10	Interleukin 10	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
9	IL18R1	Interleukin 18 Receptor 1	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
10	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
11	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
12	IL6	Interleukin 6	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
13	MB	Myoglobin	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
14	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
15	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	16.33	GeneCards inferred via : Publications (show sections)
16	CCNB3	Cyclin B3	Protein Coding	6.33	GeneCards inferred via : Publications (show sections)
17	CSF3	Colony Stimulating Factor 3	Protein Coding	6.33	GeneCards inferred via : Publications (show sections)

Sources

Variations for Bone Sarcoma

Sources

Expression for Bone Sarcoma

Search GEO for disease gene expression data for Bone Sarcoma.

Sources

Pathways for Bone Sarcoma

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 46)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.95	TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.76	TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
3	PEDF Induced Signaling ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Cytokine-cytokine receptor interaction ³⁷ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Mediated Glucocorticoid Regulation ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.52	TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.48	TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.23	TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.09	TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	12.96	TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
8	Human cytomegalovirus infection ³⁷ Show member pathways Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	12.9	TNFRSF1A SRC IL6 IL1R1 CXCL8 CCNB3
9	Allograft rejection ³⁷ ¹ Show member pathways Antigen processing and presentation ³⁷ Asthma ³⁷ Autoimmune thyroid disease ³⁷ CTL Mediated Apoptosis ⁶⁴ Graft-versus-host disease ³⁷ Intestinal immune network for IgA production ³⁷ THC Differentiation Pathway ⁶⁴ Type I diabetes mellitus ³⁷ Viral myocarditis ³⁷	12.8	TNFRSF1A IL6 IL18R1 IL10 CXCL8 CTLA4
10	Th17 cell differentiation ³⁷ Show member pathways IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²² Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.53	IL6 IL1R1 IL18R1 IL10
11	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²² Rac1/Pak1/p38/MMP-2 pathway ¹	12.52	SRC IL6 IL18R1 IL10
12	NF-kappaB Signaling ⁴	12.49	TNFRSF1A IL1RN IL10 CTLA4
13	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.33	SRC IL6 IL10 CSF3
14	Tuberculosis ³⁷	12.18	TNFRSF1A SRC IL6 IL10
15	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	12.11	IL6 IL1RN IL10 CXCL8
16	Fluid shear stress and atherosclerosis ³⁷	12.02	TNFRSF1A SRC IL1R1 GSTA1
17	Osteoclast differentiation ³⁷	11.98	TNFRSF1A IL1R1 CSF1
18	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ Th17 Differentiation Pathway ⁶⁵	11.98	IL6 IL1R1 IL18R1 IL10
19	Spinal Cord Injury ¹	11.94	IL6 IL1R1 CXCL8
20	Interleukin-4 and 13 signaling ⁶⁶	11.91	IL6 IL10 CXCL8
21	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.91	IL6 IL10 CSF3 CSF1
22	TNF signaling pathway ³⁷	11.89	TNFRSF1A IL6 IL18R1 CSF1
23	Senescence and Autophagy in Cancer ¹	11.87	SRC IL6 CXCL8
24	NF-kappa B signaling pathway ³⁷	11.85	TNFRSF1A IL1R1 CXCL8
25	Amoebiasis ³⁷	11.82	IL6 IL1R1 IL10 CXCL8
26	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.81	SRC IL6 IL10
27	Hematopoietic cell lineage ³⁷	11.81	IL6 IL1R1 CSF3 CSF1
28	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.81	TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
29	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.8	IL6 CXCL8 CSF3
30	Rheumatoid arthritis ³⁷	11.76	IL6 CXCL8 CTLA4 CSF1
31	Pertussis ³⁷	11.71	IL6 IL10 CXCL8
32	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.7	IL6 IL10 CSF1
33	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways Immune response IL-1 signaling pathway ²² Mucin expression in CF via TLRs, EGFR signaling pathways ²²	11.68	SRC IL6 IL1RN IL1R1 IL18R1 CXCL8
34	Microglia Activation During Neuroinflammation: Microglia Polarization ⁶⁵	11.67	IL6 IL1RN IL10
35	LPA receptor mediated events ¹	11.63	SRC IL6 CXCL8
36	Photodynamic therapy-induced NF-kB survival signaling ¹ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.61	TNFRSF1A IL6 CXCL8
37	Lung fibrosis ¹	11.61	IL6 CXCL8 CSF3
38	Hematopoietic Stem Cell Differentiation ¹	11.47	IL6 CSF3 CSF1
39	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.45	SRC IL6 CXCL8
40	Malaria ³⁷	11.4	IL6 IL10 CXCL8 CSF3
41	G-protein signaling_RhoB regulation pathway ²²	11.09	IL6 IL10 CXCL8 CSF3 CSF1
42	Cytokines and Inflammatory Response ¹	11.09	IL6 IL10 CSF3 CSF1
43	Overview of nanoparticle effects ¹	10.97	IL6 CXCL8
44	G-protein signaling_Rap2B regulation pathway ²²	10.94	IL6 IL10 DES CXCL8 CSF3 CSF1
45	Interleukin-10 signaling ⁶⁶	10.92	TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8
46	Syndecan-3-mediated signaling events ¹	10.91	SRC CXCL8

Sources

GO Terms for Bone Sarcoma

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.23	TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	9.76	IL6 IL1RN IL1R1 IL18R1 IL10 CXCL8
2	cellular response to lipopolysaccharide	GO:0071222	9.73	SRC IL6 IL1RN IL10 CXCL8 CSF3
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.71	IL6 IL10 CSF3
4	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.65	SRC IL6 CSF3
5	response to glucocorticoid	GO:0051384	9.61	IL6 IL1RN IL10
6	inflammatory response	GO:0006954	9.56	TNFRSF1A IL6 IL1RN IL1R1 IL18R1 IL10
7	negative regulation of B cell proliferation	GO:0030889	9.52	IL10 CTLA4
8	branching involved in mammary gland duct morphogenesis	GO:0060444	9.51	SRC CSF1
9	response to molecule of bacterial origin	GO:0002237	9.49	IL10 CXCL8
10	negative regulation of heterotypic cell-cell adhesion	GO:0034115	9.46	IL1RN IL10
11	positive regulation of T-helper 1 cell cytokine production	GO:2000556	9.4	IL1R1 IL18R1
12	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.37	IL6 IL1RN
13	response to interleukin-1	GO:0070555	9.32	SRC IL1R1
14	cytokine-mediated signaling pathway	GO:0019221	9.23	TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.26	IL6 IL10 CSF3 CSF1
2	interleukin-1 receptor activity	GO:0004908	9.16	IL1R1 IL18R1
3	cytokine activity	GO:0005125	9.1	IL6 IL1RN IL10 CXCL8 CSF3 CSF1

Sources

Sources for Bone Sarcoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia

Bone Sarcoma

Aliases & Classifications for Bone Sarcoma

MalaCards integrated aliases for Bone Sarcoma:

Characteristics:

Orphanet epidemiological data:

Classifications:

External Ids:

Summaries for Bone Sarcoma

Related Diseases for Bone Sarcoma

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Bone Sarcoma:

Symptoms & Phenotypes for Bone Sarcoma

MGI Mouse Phenotypes related to Bone Sarcoma:

Drugs & Therapeutics for Bone Sarcoma

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Genetic Tests for Bone Sarcoma

Anatomical Context for Bone Sarcoma

MalaCards organs/tissues related to Bone Sarcoma:

Publications for Bone Sarcoma

Articles related to Bone Sarcoma:

Genes for Bone Sarcoma

Genes related to Bone Sarcoma (0 elite genes):

Variations for Bone Sarcoma

Expression for Bone Sarcoma

Pathways for Bone Sarcoma

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

GO Terms for Bone Sarcoma

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

Sources for Bone Sarcoma

Inferred drug relations via UMLS ⁷² / NDF-RT ⁵¹ :